- Home
- All Stock List
- NSE
- Marksans Pharma Ltd Share Price
239.61
1.34 (0.56%)
-
Outperforms Index
45.35%
Return (1Y)
Beaten Nifty 50 by 32.46%
-
More Volatile
3.52%
Standard Deviation (1Y)
Higher than Nifty 50 by 2.54%
-
Consistent Performer
8/12
Months
beaten Nifty 50
-
AxisDirect View
No View
359
130
News & Announcements
-
Relonchem receives marketing authorization for Gabapentin 50 mg/ml oral solution
15 - May - 2025 12:00 | 1 day ago
Marksans Pharma announced that its wholly owned subsidiary Relonchem has received Marketing Authorization for the product Gabapentin 50 mg/ml oral solution from UK Medicines & Healthcare Products Regulatory Agency.
Powered by Capital Market - Live News
-
Marksans Pharma to conduct board meeting
8 days ago
-
USFDA concludes inspection of Time-Cap Laboratories' manufacturing facility in New York
28 - Apr - 2025 12:00 | 18 days ago
Marksans Pharma announced that a current Good Manufacturing Practices (cGMP) inspection was conducted by the USFDA at the manufacturing facility of the Company's wholly owned subsidiary Time-Cap Laboratories, Inc. located at 7, Michael Avenue, Farmingdale, New York, USA (?the Subsidiary?) from 16 April 2025 to 24 April 2025.
On conclusion of the inspection, the Subsidiary has received One (1) inspectional observation in Form 483. There is no data integrity observation. The Subsidiary will work closely with the USFDA and is committed to address the observation comprehensively within the stipulated time.
Powered by Capital Market - Live News
-
Marksans Pharma to conduct board meeting
8 days ago
-
USFDA concludes inspection of Time-Cap Laboratories' manufacturing facility in New York
28 - Apr - 2025 12:00 | 18 days ago
Marksans Pharma announced that a current Good Manufacturing Practices (cGMP) inspection was conducted by the USFDA at the manufacturing facility of the Company's wholly owned subsidiary Time-Cap Laboratories, Inc. located at 7, Michael Avenue, Farmingdale, New York, USA (?the Subsidiary?) from 16 April 2025 to 24 April 2025.
On conclusion of the inspection, the Subsidiary has received One (1) inspectional observation in Form 483. There is no data integrity observation. The Subsidiary will work closely with the USFDA and is committed to address the observation comprehensively within the stipulated time.
Powered by Capital Market - Live News
-
Marksans Pharma gains as USFDA concludes inspection at New York unit
28 - Apr - 2025 12:00 | 18 days ago
The inspection took place from April 16 to April 24, 2025, at the subsidiary's manufacturing facility in Farmingdale, New York.
At the end of the inspection, the subsidiary received one observation, documented in the USFDA's Form 483. Notably, the inspection did not raise any concerns regarding data integrity.
Marksans Pharma confirmed that it will work closely with the USFDA to address the observation within the prescribed timeline.
Marksans Pharma is engaged in the research, manufacturing & marketing of generic pharmaceutical formulations in the global markets. The company's manufacturing facilities are approved by several leading regulatory agencies including USFDA, UKMHRA, and Australian TGA. The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, antidiabetic, pain management, gastroenterological, and anti-allergies. the company is marketing these products globally.
The company reported a 25.6% increase in consolidated net profit to Rs 104.56 crore on a 16.3% rise in revenue from operations to Rs 681.85 crore in Q3 FY25 over Q3 FY24.
Powered by Capital Market - Live News
-
Relonchem receives marketing authorization for Gabapentin 50 mg/ml oral solution
15 - May - 2025 12:00 | 1 day ago
Marksans Pharma announced that its wholly owned subsidiary Relonchem has received Marketing Authorization for the product Gabapentin 50 mg/ml oral solution from UK Medicines & Healthcare Products Regulatory Agency.
Powered by Capital Market - Live News
-
Marksans Pharma to conduct board meeting
8 days ago
-
USFDA concludes inspection of Time-Cap Laboratories' manufacturing facility in New York
28 - Apr - 2025 12:00 | 18 days ago
Marksans Pharma announced that a current Good Manufacturing Practices (cGMP) inspection was conducted by the USFDA at the manufacturing facility of the Company's wholly owned subsidiary Time-Cap Laboratories, Inc. located at 7, Michael Avenue, Farmingdale, New York, USA (?the Subsidiary?) from 16 April 2025 to 24 April 2025.
On conclusion of the inspection, the Subsidiary has received One (1) inspectional observation in Form 483. There is no data integrity observation. The Subsidiary will work closely with the USFDA and is committed to address the observation comprehensively within the stipulated time.
Powered by Capital Market - Live News
-
Marksans Pharma gains as USFDA concludes inspection at New York unit
28 - Apr - 2025 12:00 | 18 days ago
The inspection took place from April 16 to April 24, 2025, at the subsidiary's manufacturing facility in Farmingdale, New York.
At the end of the inspection, the subsidiary received one observation, documented in the USFDA's Form 483. Notably, the inspection did not raise any concerns regarding data integrity.
Marksans Pharma confirmed that it will work closely with the USFDA to address the observation within the prescribed timeline.
Marksans Pharma is engaged in the research, manufacturing & marketing of generic pharmaceutical formulations in the global markets. The company's manufacturing facilities are approved by several leading regulatory agencies including USFDA, UKMHRA, and Australian TGA. The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, antidiabetic, pain management, gastroenterological, and anti-allergies. the company is marketing these products globally.
The company reported a 25.6% increase in consolidated net profit to Rs 104.56 crore on a 16.3% rise in revenue from operations to Rs 681.85 crore in Q3 FY25 over Q3 FY24.
Powered by Capital Market - Live News
-
Relonchem receives marketing authorization for Gabapentin 50 mg/ml oral solution
15 - May - 2025 12:00 | 1 day ago
Marksans Pharma announced that its wholly owned subsidiary Relonchem has received Marketing Authorization for the product Gabapentin 50 mg/ml oral solution from UK Medicines & Healthcare Products Regulatory Agency.
Powered by Capital Market - Live News
-
Marksans Pharma to conduct board meeting
8 days ago
-
USFDA concludes inspection of Time-Cap Laboratories' manufacturing facility in New York
28 - Apr - 2025 12:00 | 18 days ago
Marksans Pharma announced that a current Good Manufacturing Practices (cGMP) inspection was conducted by the USFDA at the manufacturing facility of the Company's wholly owned subsidiary Time-Cap Laboratories, Inc. located at 7, Michael Avenue, Farmingdale, New York, USA (?the Subsidiary?) from 16 April 2025 to 24 April 2025.
On conclusion of the inspection, the Subsidiary has received One (1) inspectional observation in Form 483. There is no data integrity observation. The Subsidiary will work closely with the USFDA and is committed to address the observation comprehensively within the stipulated time.
Powered by Capital Market - Live News
-
Marksans Pharma to conduct board meeting
8 days ago
-
USFDA concludes inspection of Time-Cap Laboratories' manufacturing facility in New York
28 - Apr - 2025 12:00 | 18 days ago
Marksans Pharma announced that a current Good Manufacturing Practices (cGMP) inspection was conducted by the USFDA at the manufacturing facility of the Company's wholly owned subsidiary Time-Cap Laboratories, Inc. located at 7, Michael Avenue, Farmingdale, New York, USA (?the Subsidiary?) from 16 April 2025 to 24 April 2025.
On conclusion of the inspection, the Subsidiary has received One (1) inspectional observation in Form 483. There is no data integrity observation. The Subsidiary will work closely with the USFDA and is committed to address the observation comprehensively within the stipulated time.
Powered by Capital Market - Live News
-
Marksans Pharma gains as USFDA concludes inspection at New York unit
28 - Apr - 2025 12:00 | 18 days ago
The inspection took place from April 16 to April 24, 2025, at the subsidiary's manufacturing facility in Farmingdale, New York.
At the end of the inspection, the subsidiary received one observation, documented in the USFDA's Form 483. Notably, the inspection did not raise any concerns regarding data integrity.
Marksans Pharma confirmed that it will work closely with the USFDA to address the observation within the prescribed timeline.
Marksans Pharma is engaged in the research, manufacturing & marketing of generic pharmaceutical formulations in the global markets. The company's manufacturing facilities are approved by several leading regulatory agencies including USFDA, UKMHRA, and Australian TGA. The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, antidiabetic, pain management, gastroenterological, and anti-allergies. the company is marketing these products globally.
The company reported a 25.6% increase in consolidated net profit to Rs 104.56 crore on a 16.3% rise in revenue from operations to Rs 681.85 crore in Q3 FY25 over Q3 FY24.
Powered by Capital Market - Live News
Stock Trivia
MF shareholding in Marksans Pharma Ltd has increased by 7.25% since past 3 Months
MF shareholding in Marksans Pharma Ltd has decreased by -20.19% since past 1 Year
MF shareholding in Marksans Pharma Ltd has increased by 7.25% since past 3 Months
FII shareholding in Marksans Pharma Ltd has increased by 141.34% since past 1 Year
MF shareholding in Marksans Pharma Ltd has decreased by -20.19% since past 1 Year
MF shareholding in Marksans Pharma Ltd has increased by 7.25% since past 3 Months
MF shareholding in Marksans Pharma Ltd has decreased by -20.19% since past 1 Year
